Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment
2007

Antiretroviral Drug Costs in Brazil

publication Evidence: moderate

Author Information

Author(s): Amy Nunn, Elize M. Fonseca, Francisco I. Bastos, Sofia Gruskin, Joshua A. Salomon

Primary Institution: Harvard School of Public Health

Hypothesis

What are the drivers of recent antiretroviral drug cost trends in Brazil?

Conclusion

Brazil has saved approximately $1 billion on antiretroviral drugs since 2001, despite rising overall treatment costs.

Supporting Evidence

  • Brazil's total drug expenditures on HAART doubled to $414 million in 2005.
  • Negotiated prices for patented drugs in Brazil were lower than in other middle-income countries.
  • Brazil's locally produced generic ARVs were generally more expensive than similar drugs made elsewhere.
  • Price reductions for patented drugs saved Brazil approximately $1.2 billion from 2001 to 2005.
  • Total costs would have been significantly lower if drug quantities had remained constant.

Takeaway

Brazil provides free HIV treatment, and while drug prices have dropped, the number of patients needing treatment has increased, leading to higher overall costs.

Methodology

The study analyzed drug-specific prices and expenditures for antiretroviral therapy in Brazil from 2001 to 2005.

Limitations

The study lacks data on patient regimen changes and does not account for price changes after 2005.

Participant Demographics

The study focuses on patients receiving highly active antiretroviral therapy (HAART) in Brazil.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0040305

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication